Silence Therapeutics PLC (LON:SLN) has added a new siRNA (short interfering RNA) asset to its pre-clinical pipeline for the potential treatment of cardiovascular disease.
The firm, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, said the proprietary product candidate, SLN360, silences apolipoprotein, a component of lipoprotein(a) (LP(a).
David Horn Solomon, of Silence Therapeutics‘ chief executive officer, commented: "We are excited to add SLN360, our new LP(a) targeting siRNA medicine, to our pipeline of wholly-owned assets aimed at addressing areas of significant unmet need.”
He added: “High LP(a) levels in humans increase the probability of significant cardiovascular disease and lowering these levels is associated with reducing cardiovascular risks and disease. Our data suggest that SLN360 significantly reduces serum LP(a) in non-human primates for up to two months and ultimately will use patient convenient sub-cutaneous dosing."
“We are poised to advance SLN360 towards the clinic as a new medicine for patients with significant cardiovascular risk," Solomon concluded.
Silence Therapeutics said that an Investigational New Drug/Clinical Trials Application for SLN360 is anticipated to be filed in the second half of 2020.
In a note to clients, analysts at ‘house’ broker Peel Hunt said: “We see this as a positive step for the company as new management focus much more on the building the pipeline – adding this to the Silence’s asset for beta-thalassemia and myelodysplastic syndrome (SLN124).”
They added: “We continue to review our valuation methodology following resolution of the recent litigation but this asset will add NPV to the portfolio/platform on a risk-adjusted basis.”
In mid-morning trading, Silence Therapeutics’ shares were 0.7% higher at 55.20p.
-- Adds analyst comment, share price --